急性呼吸窘迫综合征的宽松或保守氧疗
该多中心随机试验将ARDS患者分为保守氧疗组(目标PaO2 55–70 mmHg,SpO2 88–92%)或宽松氧疗组(目标PaO2 90–105 mmHg,SpO2 ≥96%),疗程7天,两组机械通气策略相同。主要终点为28天全因死亡。入组205例后因安全顾虑及主要终点差异可能性低而提前终止。28天保守组死亡34/99例(34.3%),宽松组27/102例(26.5%),差异7.8个百分点(95%CI -4.8至20.6);90天保守组死亡44.4%,宽松组30.4%,差异14.0个百分点(95%CI 0.7至27.2);保守组发生5例肠系膜缺血事件。
要点
- ARDS患者早期保守氧疗(PaO2 55–70 mmHg,SpO2 88–92%)28天全因死亡34.3%(34/99)vs 宽松氧疗(PaO2 90–105 mmHg,SpO2 ≥96%)26.5%(27/102),差异7.8个百分点(95%CI -4.8至20.6)。
- 90天死亡保守组44.4% vs 宽松组30.4%,差异14.0个百分点(95%CI 0.7至27.2)。
- 保守氧疗组发生5例肠系膜缺血事件。
- 试验入组205例后因安全顾虑及主要终点差异可能性低被数据与安全监察委员会提前终止。
- 两组均采用相同的机械通气策略。
适用人群与场景
- 急性呼吸窘迫综合征(ARDS)患者。
诊断标准与关键阈值
- 保守氧疗目标:PaO2 55–70 mmHg,SpO2 88–92%。
- 宽松氧疗目标:PaO2 90–105 mmHg,SpO2 ≥96%。
处置流程与药物剂量
- 保守氧疗组:目标PaO2 55–70 mmHg、SpO2 88–92%,疗程7天。
- 宽松氧疗组:目标PaO2 90–105 mmHg、SpO2 ≥96%,疗程7天。
- 两组使用相同的机械通气策略。
红旗征与不能漏的情况
- 保守氧疗组发生5例肠系膜缺血事件。
研究设计与关键结果
- 多中心随机试验,入组205例后因安全顾虑及主要终点差异可能性低被数据与安全监察委员会提前终止;排除4例不符合入选标准者。
- 28天全因死亡:保守氧疗组34/99例(34.3%)vs 宽松氧疗组27/102例(26.5%),差异7.8个百分点(95%CI -4.8至20.6)。
- 90天死亡:保守氧疗组44.4% vs 宽松氧疗组30.4%,差异14.0个百分点(95%CI 0.7至27.2)。
- 保守氧疗组发生5例肠系膜缺血事件。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(LOCO2,NCT02713451),由法国卫生部资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ARDS患者中,早期采用PaO2 55–70 mmHg的保守氧疗策略未提高28天生存率。
- 作者结论:早期保守氧疗(PaO2 55–70 mmHg)未增加28天生存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with acute respiratory distress syndrome (ARDS), the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network recommends a target partial pressure of arterial oxygen (Pao2) between 55 and 80 mm Hg. Prospective validation of this range in patients with ARDS is lacking. We hypothesized that targeting the lower limit of this range would improve outcomes in patients with ARDS.
METHODS: In this multicenter, randomized trial, we assigned patients with ARDS to receive either conservative oxygen therapy (target Pao2, 55 to 70 mm Hg; oxygen saturation as measured by pulse oximetry [Spo2], 88 to 92%) or liberal oxygen therapy (target Pao2, 90 to 105 mm Hg; Spo2, ≥96%) for 7 days. The same mechanical-ventilation strategies were used in both groups. The primary outcome was death from any cause at 28 days.
RESULTS: After the enrollment of 205 patients, the trial was prematurely stopped by the data and safety monitoring board because of safety concerns and a low likelihood of a significant difference between the two groups in the primary outcome. Four patients who did not meet the eligibility criteria were excluded. At day 28, a total of 34 of 99 patients (34.3%) in the conservative-oxygen group and 27 of 102 patients (26.5%) in the liberal-oxygen group had died (difference, 7.8 percentage points; 95% confidence interval [CI], -4.8 to 20.6). At day 90, 44.4% of the patients in the conservative-oxygen group and 30.4% of the patients in the liberal-oxygen group had died (difference, 14.0 percentage points; 95% CI, 0.7 to 27.2). Five mesenteric ischemic events occurred in the conservative-oxygen group.
CONCLUSIONS: Among patients with ARDS, early exposure to a conservative-oxygenation strategy with a Pao2 between 55 and 70 mm Hg did not increase survival at 28 days. (Funded by the French Ministry of Health; LOCO2 ClinicalTrials.gov number, NCT02713451.).
参考来源
- Barrot L, Asfar P, Mauny F, et al. Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. N Engl J Med. 2020. PMID: 32160661. doi:10.1056/NEJMoa1916431
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。